Cancer Metabolism—Oncogenic mutations affecting two isoforms of the isocitrate dehydrogenase (IDH) enzyme, IDH1 and IDH2, have been reported in approximately 30% of de novo AML and appear to be an unfavorable prognostic factor [99]. This evidence concerns the gene IDH1 and acute myeloid leukemia.